Cargando…

The risk of new-onset diabetes in antidepressant users – A systematic review and meta-analysis

BACKGROUND: Antidepressant Drugs (ADs) are among the most commonly prescribed medications in developed countries. The available epidemiological evidence suggests an association between AD use and higher risk of developing type 2 diabetes mellitus. However, some methodological issues make the interpr...

Descripción completa

Detalles Bibliográficos
Autores principales: Salvi, Virginio, Grua, Ilaria, Cerveri, Giancarlo, Mencacci, Claudio, Barone-Adesi, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536271/
https://www.ncbi.nlm.nih.gov/pubmed/28759599
http://dx.doi.org/10.1371/journal.pone.0182088
_version_ 1783253987885056000
author Salvi, Virginio
Grua, Ilaria
Cerveri, Giancarlo
Mencacci, Claudio
Barone-Adesi, Francesco
author_facet Salvi, Virginio
Grua, Ilaria
Cerveri, Giancarlo
Mencacci, Claudio
Barone-Adesi, Francesco
author_sort Salvi, Virginio
collection PubMed
description BACKGROUND: Antidepressant Drugs (ADs) are among the most commonly prescribed medications in developed countries. The available epidemiological evidence suggests an association between AD use and higher risk of developing type 2 diabetes mellitus. However, some methodological issues make the interpretation of these results difficult. Moreover, very recent studies provided conflicting results. Given the high prevalence of both diabetes and AD use in many countries, clarifying whether this association is causal is of extreme relevance for the public health. The aim of the present study is to provide an up-to-date evaluation of the evidence in support of a causal role of ADs in inducing diabetes. METHODS AND FINDINGS: A systematic literature search was conducted to identify relevant studies in MEDLINE (PubMed), PsycINFO, and International Pharmaceutical Abstracts (IPA) through 31(st) December 2016. Only studies assessing the incidence of new-onset diabetes in subjects treated with ADs were included. Results were pooled using a random-effects meta-analysis. Moreover, we extensively reviewed the role of the different sources of bias that have been proposed to explain the association between AD and diabetes. Twenty studies met the inclusion criteria. In the meta-analysis, the association between AD use and diabetes was still evident after the inclusion of the recent negative studies [pooled relative risk = 1.27, 95% confidence interval (CI), 1.19–1.35; p<0.001]. None of the biases proposed by previous authors seemed able to fully explain the observed association. CONCLUSIONS: This updated meta-analysis confirms the association between AD use and incident diabetes. It still remains a matter of debate whether single ADs exert a different effect on the risk of diabetes. Given the possible heterogeneity, we suggest that a classification of ADs according to their pharmacological profiles could be useful in better elucidating the nature of this association.
format Online
Article
Text
id pubmed-5536271
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-55362712017-08-07 The risk of new-onset diabetes in antidepressant users – A systematic review and meta-analysis Salvi, Virginio Grua, Ilaria Cerveri, Giancarlo Mencacci, Claudio Barone-Adesi, Francesco PLoS One Research Article BACKGROUND: Antidepressant Drugs (ADs) are among the most commonly prescribed medications in developed countries. The available epidemiological evidence suggests an association between AD use and higher risk of developing type 2 diabetes mellitus. However, some methodological issues make the interpretation of these results difficult. Moreover, very recent studies provided conflicting results. Given the high prevalence of both diabetes and AD use in many countries, clarifying whether this association is causal is of extreme relevance for the public health. The aim of the present study is to provide an up-to-date evaluation of the evidence in support of a causal role of ADs in inducing diabetes. METHODS AND FINDINGS: A systematic literature search was conducted to identify relevant studies in MEDLINE (PubMed), PsycINFO, and International Pharmaceutical Abstracts (IPA) through 31(st) December 2016. Only studies assessing the incidence of new-onset diabetes in subjects treated with ADs were included. Results were pooled using a random-effects meta-analysis. Moreover, we extensively reviewed the role of the different sources of bias that have been proposed to explain the association between AD and diabetes. Twenty studies met the inclusion criteria. In the meta-analysis, the association between AD use and diabetes was still evident after the inclusion of the recent negative studies [pooled relative risk = 1.27, 95% confidence interval (CI), 1.19–1.35; p<0.001]. None of the biases proposed by previous authors seemed able to fully explain the observed association. CONCLUSIONS: This updated meta-analysis confirms the association between AD use and incident diabetes. It still remains a matter of debate whether single ADs exert a different effect on the risk of diabetes. Given the possible heterogeneity, we suggest that a classification of ADs according to their pharmacological profiles could be useful in better elucidating the nature of this association. Public Library of Science 2017-07-31 /pmc/articles/PMC5536271/ /pubmed/28759599 http://dx.doi.org/10.1371/journal.pone.0182088 Text en © 2017 Salvi et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Salvi, Virginio
Grua, Ilaria
Cerveri, Giancarlo
Mencacci, Claudio
Barone-Adesi, Francesco
The risk of new-onset diabetes in antidepressant users – A systematic review and meta-analysis
title The risk of new-onset diabetes in antidepressant users – A systematic review and meta-analysis
title_full The risk of new-onset diabetes in antidepressant users – A systematic review and meta-analysis
title_fullStr The risk of new-onset diabetes in antidepressant users – A systematic review and meta-analysis
title_full_unstemmed The risk of new-onset diabetes in antidepressant users – A systematic review and meta-analysis
title_short The risk of new-onset diabetes in antidepressant users – A systematic review and meta-analysis
title_sort risk of new-onset diabetes in antidepressant users – a systematic review and meta-analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536271/
https://www.ncbi.nlm.nih.gov/pubmed/28759599
http://dx.doi.org/10.1371/journal.pone.0182088
work_keys_str_mv AT salvivirginio theriskofnewonsetdiabetesinantidepressantusersasystematicreviewandmetaanalysis
AT gruailaria theriskofnewonsetdiabetesinantidepressantusersasystematicreviewandmetaanalysis
AT cerverigiancarlo theriskofnewonsetdiabetesinantidepressantusersasystematicreviewandmetaanalysis
AT mencacciclaudio theriskofnewonsetdiabetesinantidepressantusersasystematicreviewandmetaanalysis
AT baroneadesifrancesco theriskofnewonsetdiabetesinantidepressantusersasystematicreviewandmetaanalysis
AT salvivirginio riskofnewonsetdiabetesinantidepressantusersasystematicreviewandmetaanalysis
AT gruailaria riskofnewonsetdiabetesinantidepressantusersasystematicreviewandmetaanalysis
AT cerverigiancarlo riskofnewonsetdiabetesinantidepressantusersasystematicreviewandmetaanalysis
AT mencacciclaudio riskofnewonsetdiabetesinantidepressantusersasystematicreviewandmetaanalysis
AT baroneadesifrancesco riskofnewonsetdiabetesinantidepressantusersasystematicreviewandmetaanalysis